Figure 2

a. Kaplan-Meyer estimates of time-to progression according whether vinorelbine was given alone (solid line) or combined with other agents (dashed line). Median time-to progression was 7.2 and 6.1 months for patients receiving single agent vinorelbine or vinorelbine with other chemotherapy agents (log-rank test, p = 0.76). b. Kaplan-Meyer estimates of time-to progression according whether trastuzumab was stopped (solid line) or continued (dashed line) during salvage treatment with vinorelbine. Median time-to progression was 7.1 and 6.1 months for patients stopping or continuing trastuzumab, respectively (log-rank test, p = 0.10).